 STAMFORD, Conn., April 01, 2021 GLOBE NEWSWIRE -- SpringWorks Therapeutics, Inc. Nasdaq: SWTX, a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the first patient has been dosed in a Phase 1b clinical trial evaluating nirogacestat, an investigational gamma secretase inhibitor GSI being developed by SpringWorks, in combination with teclistamab, an investigational bispecific antibody targeting B-cell maturation antigen BCMA and CD3 being developed by Janssen Research Development, LLC Janssen, in patients with relapsed or refractory multiple myeloma. 